Company Fresh2 Group Limited

Equities

FRES

US03635R2067

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Bio Diagnostics & Testing

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.3683 ^USD	+8.79%		-1.15%	-58.62%

Mar. 21	ADRs Edge Higher; Lufax Climbs Almost 46%	DJ
Mar. 19	ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	DJ

AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.

Number of employees: 75

USD in Million	2021	Weight	2022	Weight	Delta
Cancer Screening and Detection Tests 67.1 %	2	83.1 %	1	67.1 %	-48.24%
Technology Service 18.2 %	0	7.1 %	0	18.2 %	+63.06%
Physical Checkup Packages 13.1 %	0	9.2 %	0	13.1 %	-8.86%
Retail 1.7 %	0	0.6 %	0	1.7 %	+95.35%

USD in Million	2021	Weight	2022	Weight	Delta
China 100.0 %	3	100.0 %	2	100.0 %	-35.86%

Managers	Title	Age	Since
Hao Han Xu CEO	Chief Executive Officer	29	22-10-02
He Yu FOU	Founder	67	09-12-31
Chang Yu CEO	Chief Executive Officer	66	09-12-31
Jinqiu Tang DFI	Director of Finance/CFO	41	19-09-30
Xiao Yu Li DFI	Director of Finance/CFO	35	22-10-02
Du Xuedong CTO	Chief Tech/Sci/R&D Officer	44	11-03-31
Xingyan Gao SEC	Corporate Secretary	-	-
Sunil Pandit PRN	Corporate Officer/Principal	-	21-08-16
Dai Weidong PRN	Corporate Officer/Principal	64	15-03-31
Dong Cheng PRN	Corporate Officer/Principal	62	08-10-31

Members of the board	Title	Age	Since
Zhi Gang Zhao BRD	Director/Board Member	64	22-10-02
Tian Ruo Pu BRD	Director/Board Member	55	22-10-02
Chang Yu CEO	Chief Executive Officer	66	09-12-31
Xiao Yu Li DFI	Director of Finance/CFO	35	22-10-02
Hao Han Xu CEO	Chief Executive Officer	29	22-10-02
Hong Gang Tian BRD	Director/Board Member	43	22-10-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,573,100	0	0	68.46 %
Stock B	1	176,070,465	122,978,853 ( 69.85 %)	12,492,283 ( 7.095 %)

Name	Equities	%	Valuation
UBS Securities LLC 0.1411 %	33,522	0.1411 %	18 437 $
RhumbLine Advisers LP 0.0281 %	6,678	0.0281 %	3 673 $

Name	Equities	%	Valuation
Hao Han Xu 187.50 %	69,774,679	187.50 %	38 M $
ST FORTUNE GROUP LLC 38.20 %	14,214,285	38.20 %	8 M $
Chen Haowei 28.83 %	10,729,613	28.83 %	6 M $
Spring Investments Holding II LP 15.36 %	5,714,285	15.36 %	3 M $
Chang Yu 0.0180 %	6,702	0.0180 %	3 686 $

Name	Equities	%	Valuation
Chang Yu 83.23 %	2,973,900	83.23 %	2 M $

Fresh2 Group Ltd.

801 Bixing Street Bihu County

323006, Lishui

http://www.anpacbio.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
FRESH2 GROUP LIMITED	-58.62%	8.19M
EXACT SCIENCES CORPORATION	-17.60%	11.07B
IOVANCE BIOTHERAPEUTICS, INC.	+39.11%	3.16B
BGI GENOMICS CO., LTD.	-20.67%	2B
VERACYTE, INC.	-29.30%	1.46B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+11.45%	966M
SEEGENE, INC.	-6.33%	718M
CAREDX, INC	-30.75%	430M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-51.02%	348M
CURIOX BIOSYSTEMS CO., LTD	-2.58%	286M

Bio Diagnostics & Testing